These differing results in NSCLC may be partially attributed to differences in antibodies used for staining, different criteria for defining stain positivity, and different patient demographics such as histological subtype, tumor stage, adjuvant treatment, and insufficient SCC immunoreactivity. This evidence concerns the gene SERPINB3 and neoplasm.